Mesenteric adipose tissue B lymphocytes promote local and hepatic inflammation in nonalcoholic fatty liver disease mice
The IP team files patent applications covering every commercially valuable product attribute as data is generated: formulation work during Phase 2, manufacturing process optimizations during scale-up, method-of-use patents as each new indication is clinically developed, and polymorph and solvate patents following crystallization studies
CJC-1295 without DAC (Mod GRF 1-29) has a short 30-minute half-life, creating a naturalistic pulse of GH that preserves the bodys physiological rhythm
Credit/Source: Maryam Daneshpour #biosimiliar #biotech #biopharma #pharmaceuticals To view or add a comment, sign in | From regulatory greenlights to clinical milestones, September was a pivotal month for biosimilars across the globe Celltrion Inc launched Omlyclo - Europes first omalizumab biosimilar FDA approved multiple denosumab biosimilars from Henlius/Organon & Biocon Biologics - boosting bone health access in the US European Commission gave the nod to Henlius & Organons Bildyos & Bilprevda (denosumab biosimilars) EMAs CHMP issued positive opinions for several biosimilars this month Henlius Dosed First Subject In Phase 1 Trial For HLX17, a pembrolizumab biosimilar The biosimilar landscape is evolving fast - bringing innovation, affordability, and expanded access to patients worldwide
This is where steady, ongoing support adds value
A novel type of glutathione S-transferase in Onchocerca volvulus